|Bid||15.68 x 800|
|Ask||15.68 x 800|
|Day's Range||15.60 - 16.09|
|52 Week Range||5.61 - 25.10|
|Beta (3Y Monthly)||4.15|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Bank of America sees 39% upside in this marijuana stock, but a lot would need to go right for that to happen.
Jefferies analyst Owen Bennett likes Aphria and the Green Organic Dutchman, but is less impressed by Cronos Group. Where the marijuana market is going, and how to play it.
After following the cannabis industry for a couple years, Stifel analyst Andrew Carter launched formal coverage this week of Canada’s large-cap producers. He thinks that Aurora, Tilray, and Cronos Group only merit Hold ratings.
Investing.com - Most Canadian cannabis stocks lost ground again Thursday, with one notable exception: Canopy Growth (TSX:WEED) (NYSE:CGC).
Cronos Group stock was rising thanks to a two-notch upgrade from Bank of America Merrill Lynch, which argues that a move into the U.S. CBD market could be a huge opportunity for the company.
Altria stock hasn’t performed well this year, but Wells Fargo believes there’s still a bull case to be made for the stock, especially given the company’s valuable partnership with marijuana company Cronos Group.
Cronos Group: Rating and Target Price UpgradeCronos GroupEarly on June 5, Cronos Group (CRON) moved higher. The stock rose almost 14% when the market opened. The company was moving higher due to analysts’ positive notes about the cannabis
BAML Projects CBD Will Become $11.5 Billion Market by 2032BAML on CBDOn June 5, Bank of America Merrill Lynch upgraded Cronos Group (CRON) to a “buy,” citing its potential launch in the US market. BAML also estimated that the CBD market will
U.S. stocks were poised to rise again Wednesday after surging on Tuesday, as expectations grew that the Federal Reserve would cut interest rates if tariffs seriously hurt the economy.